CRANBURY, N.J., Oct. 19, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSEAmerican:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced preliminary fiscal year 2024 first quarter ended September 30, 2023 results, for Vyleesi® product revenue. Vyleesi is the first and only as-needed treatment approved by the U.S. Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).
Read more at prnewswire.comPalatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
